“International sharing of data and expertise is essential to increase the statistical robustness and medical relevance of our genomics studies in male infertility.”

Advances in genetic testing result in the discovery of numerous novel genetic variants that may play a role in male infertility each year. To assist in this feedback of knowledge, the IMIGC continuously screens the clinical validity of gene to certain types of male infertility. Following the pioneering work published in Human Reproduction [May 2019] we have recently submitted an update to be published in Human Reproduction Update 2021 (currently available from MedRvix) and in the table below we present the assessment for each infertility gene made by our panel of experts.

 It is the aim of this consortium to regularly review and publish our assessments in peer-review journals and display the results here for all to see.

Frequently asked questions:

How was this scoring performed?

Scoring is performed by at least two independent reviewers according to the Smith et al. system and we classified genes into no evidence (<3 points), limited (3-8 points), moderate (9-12 points), strong (13-15 points) or definitive (>15 points), with of a maximum of 17 points.

Why do some genes have the classification “Unable to classify”?

For some genes the inheritance pattern remains unclear or suggests polygenic inheritance, the technical quality of the identification method was too poor or the exact variant information could not be retrieved.

When is the next release scheduled?

The next release is scheduled for 2022.

Spotted a mistake, what can I do?

Please contact us via this website or email a member of this consortium.